Did FIRE-3 study results change in any way your off-protocol practice?
Will the results of the Phase III FIRE-3 study comparing first-line FOLFIRI/bevacizumab to FOLFIRI/cetuximab in patients with KRAS wt metastatic colorectal cancer (mCRC) in any way change your practice?
CALGB-80405: A phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab, or cetuximab (C225), or with the combination of bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum. NCT00265850
Heinemann V et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Proc ASCO 2013;Abstract LBA3506.
Heinemann V et al. Targeted therapy in metastatic colorectal cancer — An example of personalized medicine in action. Cancer Treat Rev 2013;39(6):592-601. Abstract
Primrose JN et al. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. Proc ASCO 2013;Abstract 3504.
Vale CL et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 2012;38(6):618-25. Abstract